The present invention relates to regimens for the treatment of angiogenic eye disorders such as DR and DME characterized by high doses of aflibercept and lengthening intervals between doses.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
The present invention relates to regimens for the treatment of angiogenic eye disorders such as nAMD, characterized by high doses of aflibercept and extended intervals between doses.
A fluid injector system includes at least one injector for pressurizing and delivering at least one fluid from at least one fluid reservoir, at least one fluid path section providing fluid communication between a bulk fluid reservoir and a syringe connected to the at least one injector, and at least one sensor arranged along the at least one fluid path section. The at least one sensor includes an emitter configured to emit light through the at least one fluid path section, and a detector configured to receive the light emitted through the at least one fluid path section and generate an electrical signal based on at least one property of the received light. The fluid injector system may further include at least one processor programmed or configured to determine, based on the electrical signal generated by the detector, at least one of an identity of the at least one fluid present in the fluid path section, a concentration of the at least one fluid in the fluid path section, and at least one property of the fluid path section.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
A61M 5/48 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for varying, regulating, indicating or limiting injection pressure
4.
EXTENDED, HIGH DOSE VEGF ANTAGONIST REGIMENS FOR TREATMENT OF ANGIOGENIC EYE DISORDERS
The present invention relates to treatment regimens characterized by high doses of aflibercept (e.g., 8 mg) and extended intervals between doses (e.g., 12 weeks) with improved visual and anatomic outcomes relative to treatment with lower doses such as 2 mg.
A fluid injector system includes at least one injector for pressurizing and delivering at least one fluid from at least one fluid reservoir, at least one fluid path section in fluid communication with the at least one injector and having a predetermined index of refraction, and a first proximal sensor and a first distal sensor arranged along the at least one fluid path section. Each of the first proximal sensor and the first distal sensor includes an emitter configured to emit light through the at least one fluid path section, and a detector configured to receive the light emitted through the at least one fluid path section and generate an electrical signal based on the received light. The fluid injector system further includes at least one processor programmed or configured to determine, based on a difference in the electrical signals generated by the first proximal sensor and the first distal sensor, at least one property of a content of the at least one fluid path section.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
A61M 5/48 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for varying, regulating, indicating or limiting injection pressure
6.
METHODS OF ADJUSTING THE PH OF A CELL CULTURE MEDIUM
Methods for adjusting the pH of a cell culture medium, methods for culturing cells in a pH-adjusted cell culture medium, and methods for making a polypeptide expressed by cells cultured in a pH-adjusted cell culture medium are described. Also described are systems for determining how much acid or base should be added to a cell culture medium to obtain a desired pH. The methods include a charge balance model that includes parameters for a functional relationship between a concentration of dissolved carbon dioxide in the cell culture medium, a mole fraction of gaseous carbon dioxide applied to the cell culture medium, a concentration of net medium acids in the cell culture medium, and the desired medium pH.
A system, method, and computer program product for protocol conversion may obtain a fixed protocol including the following fixed protocol parameters: a flow rate of at least one fluid to be delivered to a patient in at least one phase of an injection and a volume of the at least one fluid to be delivered to the patient in the at least one phase of the injection; provide a series of prompts, and receive a series of user responses in response to the series of prompts; and generate, based on the series of user responses and the fixed protocol, a smart protocol including the following smart protocol parameters according to which the injection system is configured to control delivery of the at least one fluid to the patient in the injection: a dosing factor and a dosing method.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
8.
CONCENTRATED LIQUID GEL FORMULATIONS CONTAINING NAPROXEN SALTS
This disclosure is in the field of mini-softgel capsules, particularly softgel capsules containing naproxen salt as an active ingredient. It relates generally to softgel capsules containing high concentration formulations of naproxen sodium.
A cassette for holding fluid path components for a fluid injector may include a body defining at least one feature for holding at least one fluid path component for the fluid injector; and a connecting member for removably connecting the body of the cassette to the fluid injector, the connecting member operatively connected to the body, wherein the connecting member comprises at least one pivotable connecting feature protruding from the body, and wherein each of the at least one pivotable connecting feature is configured for removably connecting to a corresponding connecting feature receiver on the fluid injector such that the body is pivotally movable relative to the fluid injector between a first, unlatched position and a second, latched position in which the at least one fluid path component on the body of the cassette is positioned for operative connection to a corresponding feature of the fluid injector.
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
The present disclosure relates generally to bilayer tablets comprising a combination of two active pharmaceutical ingredients, and more specifically to bilayer tablets comprising acetylsalicylic acid, pseudoephedrine, and a dissolution aid. The bilayer tablets utilize a combination of granulated and non-granulated acetylsalicylic acid along with a unique distribution of sodium carbonate as a dissolution aid that provide acetylsalicylic acid and pseudoephedrine in a single dosage form having rapid dissolution and long-term storage stability (low degradation). The present disclosure also provides methods of preparing and of using the bilayer tablets.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/616 - Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
This disclosure relates to auto-injectors and their method of use with pre-filled syringes. The embodiments include an auto-injector system for injecting various solution volumes, including: an auto-injector housing having an actuating end and an injection end, the housing including; a release mechanism co-axially aligned in the housing near the actuating end; a spring co-axially aligned and in contact with the release mechanism; a pre-filled syringe co-axially aligned in the housing at the injection end, including a set capacity syringe barrel having a syringe chamber for holding a plunger cap with a plunger cap length and a solution volume for injecting, wherein the plunger cap retains the solution volume within the syringe chamber; and a syringe needle attached to the syringe barrel for injecting the solution volume; an interchangeable plunger rod that's interchangeable having a defined interchangeable plunger rod length and being co-axially aligned in the housing between the spring and the plunger cap; and an interchangeable plunger rod extension that's interchangeable having a defined interchangeable plunger rod extension length and being coaxially aligned and contacting the interchangeable plunger rod, wherein the lengths of the spring, interchangeable plunger rod, interchangeable plunger rod extension, and plunger cap define a co-axially aligned and continuous auto-injector system for injecting various solution volumes; and an optional auto-injector cap for covering the auto-injector housing at the injection end. The embodiments further provide methods for injecting various solution volumes using an auto-injector system, including: providing an auto-injector system for injecting various solution volumes, including an auto-injector housing having an actuating end and an injection end, the housing including a release mechanism co-axially aligned in the housing near the actuating end; a spring co-axially aligned and in contact with the release mechanism; a pre-filled syringe co-axially aligned in the housing at the injection end, including a set capacity syringe barrel having a syringe chamber for holding a plunger cap with a plunger cap length and a solution volume, wherein the plunger cap retains the solution volume within the syringe chamber; and a syringe needle attached to the syringe barrel for injecting the solution volume; an interchangeable plunger rod having a defined interchangeable plunger rod length and being co-axially aligned in the housing between the spring and the plunger cap; and an interchangeable plunger rod extension having a defined interchangeable plunger rod extension length and being co-axially aligned and contacting the interchangeable plunger rod, wherein the lengths of the spring, interchangeable plunger rod, interchangeable plunger rod extension, and plunger cap define a co-axially aligned and continuous auto-injector system for injecting various solution volumes; and an optional auto-injector cap for covering the auto-injector housing at the injection end; and injecting the various solution volumes.
A system for securely accessing a fluid injection system is disclosed. The system includes at least one processor programmed or configured to authenticate a user for access to an fluid injection system, provide data identifying one or more features of a software application for accessing the fluid injection system, receive data identifying a selected feature of the software application for accessing the fluid injection system, and provide access to the selected feature of the software application for accessing the fluid injection system.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
The present embodiments relate to pathogen clearance. Subject matter of the present embodiments are computer-implemented methods, computer systems and computer-readable storage media for predicting the performance of pathogen clearance processes.
G16C 20/00 - Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
G16C 20/70 - Machine learning, data mining or chemometrics
C07K 1/16 - Extraction; Separation; Purification by chromatography
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
A prime tube includes a sidewall defining an internal chamber having an expandable volume, a connecter associated with a proximal end of the sidewall and configured to reversibly engage an outlet of a fluid reservoir containing a medical fluid, and a closure associated with a distal end of the sidewall, the closure permeable to air and substantially impermeable to the medical fluid. The expandable volume of the internal chamber is configured to increase as the medical fluid enters the internal chamber.
A61M 5/38 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body using hydrophilic or hydrophobic filters
A61M 39/00 - Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
A61M 39/08 - Tubes; Storage means specially adapted therefor
A61M 39/20 - Closure caps or plugs for connectors or open ends of tubes
A syringe including a proximal end, a distal end, and a cylindrical sidewall extending between the proximal end and the distal end, wherein the distal end comprises a conical distal end wall and a fluid nozzle at a distal end of the conical distal end wall; a cylindrical load bearing wall extending axially from the cylindrical sidewall past a proximal end of the conical distal end wall; and a plurality of radial ribs positioned around a periphery of the conical distal end wall, wherein a longitudinal axis of the plurality of radial ribs extends radially inward from the cylindrical load bearing wall towards the fluid nozzle over at least a portion of the conical distal end wall.
Provided is a system for enabling communication between a fluid injection system and at least one of a plurality of external systems. The system includes a gateway device and the gateway device includes at least one processor programmed or configured to provide a first communication interface between a hospital information system and a fluid injection system, provide a second communication interface between a fluid injection system service and control system associated with the fluid injection system and the fluid injection system, and provide a third communication interface between a medical imaging system and the fluid injection system.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
An apparatus (300) for suspending air bubbles in a fluid path of a fluid injector system includes an internal chamber (320) having a curved interior wall (322) defined within the housing (310), an inlet fluid pathway in fluid communication with the internal chamber, and an outlet fluid pathway in fluid communication with the internal chamber. The inlet fluid pathway extending into the chamber at a tangent to the curved interior wall, and the outlet fluid pathway spaced from the inlet fluid pathway such that fluid flowing into the internal chamber via the inlet fluid pathway is directed away from the outlet fluid pathway. The internal chamber is configured to create an internal fluid vortex in an injection fluid entering the internal chamber from the inlet fluid pathway, and wherein the internal fluid vortex at least temporarily suspends air bubbles in the fluid in the internal vortex and delays the passage of the air bubbles to the outlet fluid pathway.
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
18.
SYSTEM AND METHOD FOR SYRINGE PLUNGER ENGAGEMENT WITH AN INJECTOR
A plunger (326) for use with a syringe includes a plunger body (332) defining a central longitudinal axis (334) and having a proximal end (336), a distal end (338), and a circumferential sidewall (339) connecting the proximal end and the distal end. The plunger further includes at least one retaining member (368) associated with and extending proximally from the plunger body. The at least one retaining member has a first end connected to the plunger body, a second end proximal to the first end and radially and resiliently deflectable relative to the first end, and at least one catch (374) on the second end. A fluid injector system includes a piston (400) having a plunger engagement mechanism configured for interacting with the at least one retaining element of the plunger to releasably engage the plunger for reciprocally driving the plunger within a barrel of the syringe.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/315 - Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod; Appliances on the rod for facilitating dosing
19.
SYSTEM, METHOD, AND COMPUTER PROGRAM PRODUCT FOR CONTROLLING A FLUID INJECTION SYSTEM BASED ON HYDRAULIC RESISTANCE
A system for controlling a fluid injection system is disclosed. The system includes at least one processor programmed or configured to determine at least one characteristic of a power injection protocol, where the at least one characteristic of the power injection protocol is associated with a medical fluid involved in the power injection protocol, determine an estimated value of viscosity of the medical fluid based on the at least one characteristic of the power injection protocol, calculate a hydraulic resistance score based on the estimated value of viscosity of the medical fluid, and determine one or more motor controller gains of a motor of a powered fluid injector in the power injection protocol based on the hydraulic resistance score.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
20.
SYSTEM, METHOD, AND COMPUTER PROGRAM PRODUCT FOR PROVIDING QUICK RESPONSE (QR) CODES FOR INJECTION SYSTEMS
A system for providing a quick response (QR) code associated with an injection system is disclosed. The system includes the injection system and at least one processor. The at least one processor is programmed or configured to: receive data associated with the injection system; generate a network resource based on the data associated with the injection system, wherein, when generating the network resource, the at least one processor is programmed or configured to encode the data associated with the injection system into the network resource; generate a QR code based on the network resource; and display the QR code on a display screen of the injection system.
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
G06F 16/955 - Retrieval from the web using information identifiers, e.g. uniform resource locators [URL]
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
G06K 19/06 - Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
H04L 9/00 - Arrangements for secret or secure communications; Network security protocols
21.
SYSTEM, DEVICE, AND METHOD FOR SAFEGUARDING WELLBEING OF PATIENTS FOR FLUID INJECTION
A system and method for promoting and safeguarding the wellbeing of patients in relation to a fluid injection may obtain patient data; determine, based on the patient data, an initial risk prediction for a patient for a fluid injection to be administered to the patient, the initial risk prediction including a probability that the patient experiences at least one adverse event in response to the fluid injection; provide, to a user device, before the fluid injection is administered to the patient, the initial risk prediction; determine, after the fluid injection is started, sensor data associated with the patient; determine, based on the sensor data determined after the fluid injection is started, a current risk prediction including a probability that the patient experiences the at least one adverse event in response to the fluid injection; and provide, to the user device, the current risk prediction.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
22.
SYSTEM, DEVICE, AND METHOD FOR SAFEGUARDING WELLBEING OF PATIENTS FOR FLUID INJECTION
A system and method for promoting and safeguarding the wellbeing of patients in relation to a fluid injection may obtain patient data; determine, based on the patient data, an initial risk prediction for a patient for a fluid injection to be administered to the patient, the initial risk prediction including a probability that the patient experiences at least one adverse event in response to the fluid injection; provide, to a user device, before the fluid injection is administered to the patient, the initial risk prediction; determine, after the fluid injection is started, sensor data associated with the patient; determine, based on the sensor data determined after the fluid injection is started, a current risk prediction including a probability that the patient experiences the at least one adverse event in response to the fluid injection; and provide, to the user device, the current risk prediction.
A system and method for promoting and safeguarding the wellbeing of patients in relation to a fluid injection may obtain patient data; determine, based on the patient data, an initial risk prediction for a patient for a fluid injection to be administered to the patient, the initial risk prediction including a probability that the patient experiences at least one adverse event in response to the fluid injection; provide, to a user device, before the fluid injection is administered to the patient, the initial risk prediction; determine, after the fluid injection is started, sensor data associated with the patient; determine, based on the sensor data determined after the fluid injection is started, a current risk prediction including a probability that the patient experiences the at least one adverse event in response to the fluid injection; and provide, to the user device, the current risk prediction.
This disclosure relates to pre-fill ed syringes and their methods for use and injection. The embodiments provide a pre-filled syringe system for controlled depth of injection in a subject, including a pre-fill ed syringe having a needle tip and a plunger for injecting the contents of the pre-filled syringe; a housing for holding the pre-filled syringe and needle tip in a defined position for a depth of injection; and a needle shield mounted on the housing for releasable movement from a locked injection position to a shield position, wherein after the needle shield is moved into the locked injection position with the needle tip extended out of the needle shield and pre-filled syringe system, the needle can be inserted into the subject at a defined depth of injection. The embodiments further provide methods of injecting a subject using a pre-filled syringe system, including providing a pre-filled syringe system having a housing, a needle shield mounted on the housing, and a pre-filled syringe with a needle tip; moving the needle shield mounted on the housing into a locked injection position to extend the needle tip of the pre-filled syringe and system at a defined length out of the needle shield and pre-filled syringe system; inserting the needle tip of the pre-filled syringe and system into a subject at a defined injection depth, and injecting the contents of the pre-filled syringe and system into the subject.
A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
A61M 5/46 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for controlling depth of insertion
25.
SYSTEM FOR AIR VOLUME CORRECTION BASED ON FLUID PRESSURE AND FLOW RATE
A method for determining a volume of one or more air bubbles in a fluid path includes initiating an injection procedure in which at least one medical fluid is injected into the fluid path, receiving an electrical signal from an air detector of the fluid injector system, wherein the electrical signal indicates the presence of one or more air bubbles in the fluid path, calculating a flow rate of fluid in the fluid path, determining a fluid pressure in the fluid path, determining a count value of the one or more air bubbles representative of a volume of the one or more air bubbles, and updating a cumulative counter with the count value of the one or more air bubbles. The cumulative counter is representative of a cumulative volume of air that has passed through the fluid path during the injection procedure.
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
A fluid mixing device for mixing a first injection fluid and a second injection fluid includes a first fluid inlet, a second fluid inlet, a mixing chamber in fluid communication with the first and second fluid inlets, and an outlet port in fluid communication with the mixing chamber. The first fluid inlet is configured to conduct the first injection fluid in a first direction and has a first redirecting surface. The second fluid inlet is configured to conduct the second injection fluid in a second direction along a different axis from the first direction and has a second redirecting surface. The mixing chamber is configured to mix the first injection fluid and the second fluid together. The mixture of the first injection fluid and the second injection fluid exits the fluid mixing device via the outlet port.
A fluid path connector for a medical fluid delivery system, the fluid path connector including a first connector element comprising a body, a first lumen, a first flexible leg, and a second flexible leg, and a second connector element comprising a body defining an undercut, a second lumen, a channel defined in the body, and at least one sealing element positioned within the channel, in which the first flexible leg comprises a first flange and the second flexible leg comprises a second flange, and in which, upon engagement of the first connector element with the second connector element, the first flange and the second flange engage with the undercut of the body of the second connector element to prevent disengagement of the first connector element and the second connector element.
The present disclosure relates to oral naproxen sodium tablets comprising roller-compacted granules, methods of preparing thereof, and methods of using thereof. The naproxen sodium tablets are formulated for and prepared by dry granulation methods, specifically roller compaction. The combination of dry granulation compatible excipients with roller compaction methods results m naproxen sodium tablets that exhibit an enhanced dissolution profile and shorter disintegration time as compared to commercially available oral naproxen sodium tablets prepared by standard wet granulation methods.
A method, system, and computer program product are disclosed for performance monitoring of a smart fluid injector system having at least one sensor configured for detecting operation data. The operation data includes one or more operation parameters associated with at least one of: one or more drive components of the fluid injector system and at least one disposable component configured for use with the fluid injector system. The fluid injector system further includes a control device having at least one processor programmed or configured to: receive the operation data, and determine a component status for at least one of: the drive component(s), the disposable component(s), and administration line(s) by comparing the received operation data with stored operation data. The component status includes one or more predictions of an operation failure or a misuse of at least one of: the drive component(s), the disposable component(s), and administration line(s).
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
31.
SYSTEM, METHOD, AND COMPUTER PROGRAM PRODUCT FOR OCCLUSION DETECTION AND IMPROVED PRESSURE LIMITING BEHAVIOR FOR FLUID INJECTOR DEVICES
A system, method, and computer program product are disclosed for occlusion detection and/or pressure limiting in a fluid injector system during an injection procedure. The fluid injector system may determine a pressure differential between the first fluid pressure measurement and the second fluid pressure measurement, continuously calculate a change in compliance volume of the at least one fluid injector device based on the determined pressure differential, compare the calculated change in compliance volume with the predetermined fluid flow rate, and determine whether an occlusion or a partial occlusion has occurred downstream of the at least one fluid injector device. If an occlusion or partial occlusion is detected, the user may be notified and the injection procedure halted to prevent harm to the patient.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
A61M 5/48 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for varying, regulating, indicating or limiting injection pressure
The present disclosure is directed to capsules, for example, softgel capsules for oral administration that have on their surface laser etching that penetrates at least partially into the surface of the capsule, reduces the structural integrity of the capsule while preventing exposure of the interior contents to the outside environment, and increases the rate of release of active ingredients contained within.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating
33.
PRESSURE JACKETS AND SYRINGE RETENTION FEATURES FOR ANGIOGRAPHY FLUID INJECTORS
An assembly for retaining a pressure jacket (134) and a syringe (132) on a fluid injector, the assembly including a base plate (1902) comprising a body (1904); at least a first retaining arm (1910a) and a second retaining arm (1910b) operatively mounted on the body of the base plate, the first retaining arm having a first retaining surface at a distal end thereof and the second retaining arm having a second retaining surface at a distal end thereof, wherein the first retaining surface and the second retaining surface are configured for abutting a distal surface of at least one of the pressure jacket and the syringe; a linkage assembly operatively connected to at least one of the first retaining arm and the second retaining arm, wherein the linkage assembly is configured to move at least one of the first retaining arm and the second retaining arm between at least a first open position and a closed position.
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
Provided are topical analgesic spray compositions and topical analgesic spray concentrates containing menthol and camphor in high concentrations. The present disclosure also provides organoleptic compositions for use in the topical analgesic spray compositions and concentrates to provide enhanced sensory experience and long-lasting pain-relief.
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Provided are topical analgesic gel compositions having relatively high payloads of menthol and camphor by micro-emulsion technology and methods of preparing topical analgesic gel compositions having relatively high payloads of menthol and camphor. Topical analgesic gel compositions may include from 12 to 16 vvt. % menthol; from 4 to 8 wt % camphor; from. 0.1 to 2 wt. % carbomer; and 60 to 70 wt. % solvent. Topical analgesic gel compositions can have a viscosity from 60,000 to 110,000 centipoise.
A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Provided are topical analgesic compositions and methods of preparing topical analgesic compositions comprising a stable nano-encapsulating matrix film. The topical analgesic compositions and methods of preparing topical analgesic compositions may be suited for roll-on applicators. Topical analgesic compositions may include 12 to 16 wt. % menthol; 4 to 8 wt. % camphor; 2 to 15 wt. % film-forming polymer; and 50 to 70 wt. % solvent. To be used in a roll-on applicator, the topical analgesic composition has a viscosity from 800 to 1400 centipoise.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
37.
NOVEL HIGH FIDELITY RNA-PROGRAMMABLE ENDONUCLEASE SYSTEMS AND USES THEREOF
Described herein are novel systems for targeting, editing or manipulating DNA in a cell, using novel M- SmallCas9 nucleases and variants thereof. The M-SmallCas9 nucleases are derived from wildtype or parental small type II CRISPR Cas9 endonucleases, and display improved fidelity compared to parental type II CRISPR Cas9 enzymes in combination with a simple PAM sequences and are small endonuclease size.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Provided herein, in some embodiments, are materials and methods for treating hemophilia A in a subject ex vivo or in vivo. Also provided herein, in some embodiments, are materials and methods for knocking in a coding sequence encoding a synthetic FVIII having a B domain substitute into a genome.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The present disclosure relates generally to topical analgesic compositions comprising nonsteroidal anti-inflammatory drugs, and more specifically to topical gel compositions of naproxen in combination with select neutralizing agents, thereby having enhanced skin permeation and skin retention properties as well as improved aesthetics upon application and drying.
A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
40.
MECHANISMS FOR PREVENTING RECONNECTION OF CONNECTORS INTENDED FOR SINGLE USE
A single-use connector configured to be removably connected to a reusable connector includes a hollow, tubular housing having an open proximal side opposite a distal side along a longitudinal length of the housing and at least one guard member connected to the tubular housing. The at least one guard member is configured to transition between an open position, in which the single-use connector can be connected to the reusable connector, and a closed position in which the guard member prevents the single-use connector from being connected to the reusable connector. Disconnecting the single-use connector from the reusable connector causes the at least one guard member to transition from the open position to the closed position. A single-use disposable set (SUDS) including a single-use connector and at least use guard member for preventing reconnection of the connector to a reusable connector or fluid port is also disclosed.
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
The present disclosure relates generally to novel lipid nanoparticle (LNP)-based compositions useful for, e.g., the delivery of a site-specific endonuclease or a nucleic acid molecule encoding same, into a target cell. Some embodiments of the disclosure relate to compositions and methods for editing the genome of a cell, which involve contacting the cell with an LNP composition as described herein.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
42.
VIRAL INACTIVATION METHODS FOR CONTINUOUS MANUFACTURING OF ANTIBODIES
This disclosure relates to methods for use in inactivating viruses. The virus inactivation methods are for use in continuous process manufacturing of a biologic such as an antibody, and include separating an eluate using a column, subjecting said eluate to an orthogonal treatment of low pH and detergent simultaneously wherein, the time for viral inactivation is reduced. In addition, the detergent can be added to buffer system in purification process to achieve the same effect. The biologic in each treatment case is retained.
The present application relates to compositions and methods for genome editing in cells by homology-independent mechanisms, in particular for genome editing in cells that lack the machinery necessary for repair by homology-dependent mechanisms.
Provided herein are compositions, methods, and systems for targeted delivery of nucleic acids, including DNA and RNA, to a target cell. Also provided are compositions, methods, and systems for expressing a transgene in a cell by genomic editing. Further provided are compositions, methods, and systems for knocking in a gene-of-interest (GOI) into a target genomic locus in the genome, in particular the locus of albumin gene. Also provided are compositions, methods, and systems for treating a subject having or suspected of having a disorder or health condition employing ex vivo and/or in vivo genome editing.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/90 - Stable introduction of foreign DNA into chromosome
45.
FLUID INJECTOR SYSTEM, METHOD OF PREVENTING FLUID BACKFLOW, AND COMPUTER PROGRAM PRODUCT
A fluid injector system includes a control device operatively associated with each of two or more drive components configured to pressurize and inject a first fluid from a first fluid reservoir through a fluid conduit, and at least a second fluid from a second fluid reservoir through the fluid conduit. The fluid conduit is in selective fluid communication with the first and second fluid reservoirs. The control device has at least one processor programmed or configured to actuate a second drive component to pressurize and inject the second fluid through the fluid conduit, and while the second drive component is actuated, actuate a first drive component to introduce intermittent pulses of the first fluid to create a flow front interface between the first fluid and the second fluid in the fluid conduit to prevent backflow of the second fluid through the fluid conduit into the first fluid reservoir.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A fluid injector system configured to perform an injection protocol in connection with a diagnostic imaging procedure includes a memory for storing a predetermined pressure profile representative of pressure expected to be generated within an exemplary administration line by a priming fluid, and a control device operatively associated with a drive component to pressurize and inject at least one fluid through a subject administration line. The control device includes a processor configured to perform an operation including: actuating the drive component to prime the subject administration line; determining a distinct pressure profile indicative of a measurement of current pressure generated during the priming of the subject administration line; comparing the distinct pressure profile to the predetermined pressure profile; and determining, based on a result of the comparison, whether the subject administration line, prior to priming, contained at least one of a liquid or a gas as the extant fluid.
A fluid injector system includes a control device operatively associated with a first drive component configured to pressurize and inject a first fluid and a second drive component configured to pressurize and inject a second fluid. The control device includes at least one processor programmed or configured to: during a first phase of a multi-phase injection protocol, actuate at least the first drive component to inject the first phase; during the first phase of the injection protocol and prior to transitioning to a second phase of the injection protocol, actuate the second drive component to pressurize the second fluid relative to a pressure of the first fluid; and during the second phase of the injection protocol, actuate the second drive component to inject at least the second fluid so that a desired steady-state ratio of the first fluid and the second fluid in the second phase is reached.
The present disclosure relates to an aqueous-based composition containing one or more natural polymers and two or more natural polyols, where the aqueous-based composition is formulated to inhibit microbial growth without utilizing any added artificial preservatives.
The present disclosure relates generally to pharmaceutical formulations of oxymetazoline and, more specifically, formulations of oxymetazoline containing one or more transition metal additives and having enhanced stability against degradation.
A rolling diaphragm syringe has a proximal end having an end wall, a distal end, and a sidewall extending between the proximal end and the distal end. The rolling diaphragm syringe further has a piston engagement portion protruding proximally from a central portion of the end wall, the piston engagement portion having a central axis, and a plurality of grooves recessed inward relative to an outer surface of the piston engagement portion. The grooves are spaced apart from each other in a direction about the central axis. The piston engagement portion is configured for engagement with at least one engagement element of a piston of a fluid injector at least during movement of the piston in a proximal direction.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/315 - Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod; Appliances on the rod for facilitating dosing
51.
HIGH CONCENTRATION SUSPENSION FORMULATION FOR COLD AND FLU SOFT GEL CAPSULE MEDICATIONS
The present disclosure provides for suspension-based pharmaceutical formulations for cold and flu medications, specifically suspension formulations and soft gel capsule dosage forms having reduced size. The present disclosure also provides methods of preparing the suspensions and soft gel capsule dosage forms.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/4402 - Non-condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
52.
SYSTEM AND METHOD FOR AIR DETECTION IN FLUID INJECTOR
An injector system for delivering a medical fluid may include at least one syringe defining a reservoir operatively connected to a piston; and at least one processor programmed or configured to, based on an air check protocol for detecting air in the reservoir, determine a baseline value comprising baseline compressibility data for the at least one syringe of the injector system, deliver the first amount of the medical fluid from the reservoir; refill the reservoir with a second amount of the medical fluid; based on the air check protocol, perform an air check pressurization sequence by gathering air check compressibility data for the at least one syringe of the injector system; and based on the air check protocol, compare the air check compressibility data with the baseline compressibility data to determine a volume of air present in the reservoir.
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
53.
NOVEL RNA-PROGRAMMABLE ENDONUCLEASE SYSTEMS AND USES THEREOF
Aspects of this invention, inter alia, relate to novel systems for targeting, editing or manipulating DNA in a cell, using novel synthetic RNA-guided nucleases (sRGNs). The sRGNs are derived from wildtype or parental small type II CRISPR Cas9 endonucleases.
A method is provided for authenticating, and establishing and tracking eligibility of a patient to purchase an over-the-counter (OTC) drug from a retailer, the patient using a client device or terminal and the retailer having a server. The server is 5 configured to redirect the client device or terminal to a backend platform to authenticate the patient, access a storage to search for any information that indicates the patient is ineligible to purchase the OTC drug; and without any information that indicates the patient is ineligible, administer a questionnaire to the patient to assess the eligibility for the OTC drug. And the backend platform redirects the client device 10 or terminal back to the server to complete the online sale of the OTC drug to the patient when the patient is eligible, or cancel the online sale of the OTC drug to the patient when the patient is ineligible.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
A fluid injector system has at least one reciprocally operable piston having a piston head, and a plunger engagement mechanism associated with the piston head. The plunger engagement mechanism has a cam sleeve disposed within the piston head and movable relative to the piston head, the cam sleeve having one or more tracks defining a cam surface. The plunger engagement mechanism further has an actuator operatively connected to the cam sleeve for moving the cam sleeve relative to the piston head, and one or more pins disposed within the cam sleeve. The one or more pins are movable within the one or more tracks with movement of the cam sleeve between a first or withdrawn position, wherein the one or more pins are radially withdrawn into the piston head and a second or extended position, wherein the one or more pins protrude radially outward relative to an outer surface of the piston head.
A syringe rolling apparatus for initial rolling of a rolling diaphragm syringe from an unrolled state to a rolled state has a pressure jacket configured for receiving an empty, unrolled rolling diaphragm syringe, a piston reciprocally movable within the pressure jacket and configured for contacting an end wall of the syringe rolling diaphragm syringe to initiate a rolling of a flexible sidewall of the rolling diaphragm syringe, and a seal assembly configured for engaging an open discharge neck of the rolling diaphragm syringe. The seal assembly is in fluid communication with a source of pressurized fluid to pressurize an interior of the rolling diaphragm syringe during a distal movement of the piston. A method for initial rolling of a rolling diaphragm syringe from an unrolled state to a rolled state is also disclosed.
The embodiments provide a modified filter membrane for separating a crude solution of a biological product and a viral contaminant. The filter membrane has a cellulosed based porous surface, and at least one divalent metal ion bound to the cellulose based porous surface of the filter membrane to form a modified filter membrane cellulose based porous surface, wherein the modified cellulose based porous surface separates the crude solution by retaining a viral contaminant greater than 15 nm in diameter while allowing a biological product smaller than 15 nm in diameter to pass through. The embodiments also provide a method of filtering a crude solution of a biological product and a viral contaminant using a modified filter membrane by adding a divalent metal ion to a filter membrane porous surface to form a modified filter membrane porous surface with a pore size in the range of 1 to 15 nm in size, and filtering the crude solution of the biological product and the viral contaminant through the porous surface of the modified filter membrane, wherein the modified filter membrane retains the viral contaminant on the porous surface while allowing the biological product to pass through.
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
A rolling diaphragm syringe for receiving a medical fluid therein, the rolling diaphragm syringe comprising a sidewall that is flexible and rolls upon itself when acted upon by the piston such that an outer surface of the sidewall is rolled in a radially inward direction as the piston is advanced from the proximal end to the distal end, and wherein at least a portion of an inner surface of the flexible sidewall comprises at least one surface texturization feature.
Provided include compositions, methods, and systems for modulating the expression, function, and/or activity of a target gene, for example a blood-clotting protein such as Factor VIII (FVIII), in a cell by genome editing. Also provided include compositions, methods, and systems for treating a subject having or suspected of having a disorder or health condition, e.g., Hemophilia A, employing ex vivo and/or in vivo genome editing.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/90 - Stable introduction of foreign DNA into chromosome
60.
MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2A
The present application provides materials and methods for treating a patient with Usher Syndrome Type 2A, both ex vivo and in vivo; materials and methods for editing a USH2A gene in a human cell; materials and methods for editing an USH2A gene containing an IVS40 mutation; materials and methods for treating a patient with an USH2A gene containing an IVS40 mutation; and a method for deleting a sequence comprising an IVS40 mutation within a USH2A gene of a cell. The present application also provides one or more gRNAs or sgRNAs for editing an USH2A gene containing an IVS40 mutation. The present application provides a therapeutic for treating a patient with Usher Syndrome Type 2A. The present application also provides a kit for treating a patient with Usher Syndrome Type 2A.
The present application provides materials and methods for treating a patient with one or more of Usher Syndrome Type 2A and ARRP, both ex vivo and in vivo; materials and methods for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299. In addition, the present application provides one or more gRNAs or sgRNAs for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299; a therapeutic comprising at least one or more gRNAs or sgRNAs for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299; and a therapeutic for treating a patient with one or more of Usher Syndrome Type 2A and ARRP. The present application also provides a kit for treating a patient with one or more of Usher Syndrome Type 2A and ARRP.
The present application provides materials and methods for treating a patient with autosomal dominant CORD, both ex vivo and in vivo; materials and methods for editing a GUCY2D gene in a human cell; and materials and methods for editing a R838H, R838C, or R838S mutation in a GUCY2D gene in a human cell. The present application also provides one or more gRNAs or sgRNAs for editing a GUCY2D gene; one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene; and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene. The present application provides a therapeutic for treating a patient with autosomal dominant CORD. The present application also provides a kit for treating a patient with autosomal dominant CORD. In addition, the present application provides a self-inactivating CRISPR-Cas system.
The invention concerns a die insertion tool (100) for inserting a die (550) into a die pocket (552) of a press (500), the tool (100) includes a barrel (102) shaped for positioning the tool (100) within a punch guide bore (582) of the press (500), a tip (106) for insertion into a die cavity (556) of the die (550), and a collar (104) located between the barrel (102) and the tip (106) and configured to contact the die (550) when the tip (106) is inserted in the die cavity (556). The invention further concerns a kit (700) for a press (500) and a method for inserting a die (550) into a die pocket (552) of a press (500),
B30B 11/08 - Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses or tabletting presses using a ram exerting pressure on the material in a moulding space co-operating with moulds carried by a turn-table
B30B 15/02 - Dies; Inserts therefor or mountings thereof; Moulds
64.
MATERIALS AND METHODS FOR TREATMENT OF AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA
The present application provides materials and methods for treating a patient with autosomal dominant RP, both ex vivo and in vivo; materials and methods for editing a RHO gene in a human cell; and materials and methods for editing a P23H mutation in a RHO gene in a human cell. In addition, the present application provides one or more gRNAs or sgRNAs for editing a RHO gene; one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene; and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene. The present application provides a therapeutic for treating a patient with autosomal dominant RP. The present application provides a kit for treating a patient with autosomal dominant RP. In addition, the present application provides a self-inactivating CRISPR-Cas system.
Provided include materials and methods for treating Hemophilia A in a subject ex vivo or in vivo. Also provided include materials and methods for knocking in a FVIII-encoding gene in a genome, in particular the locus of albumin gene.
This disclosure relates to methods for the prevention of the reduction of disulfide bonds in a polypeptide expressed in a recombinant host cell, comprising, following fermentation, adding phosphate to a harvest solution of the recombinant host cell, wherein the disulfide bond in the polypeptide remains non-reduced.
This disclosure relates to methods for the prevention of the reduction of disulfide bonds in a polypeptide expressed in a recombinant host cell, comprising, following fermentation, adding selenite and/or its salts or derivatives to a harvest solution of the recombinant host cell, wherein the disulfide bond in the polypeptide remains non-reduced.
C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/00 - Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
A cap for intake and delivery of a fluid from a syringe is described. The cap includes an outer cap assembly comprising a fluid inlet path and a fluid outlet path and an inner cap assembly configured for insertion into a fluid nozzle of the syringe and to provide selective fluid communication between an interior of a syringe and the fluid inlet path or the fluid outlet path. The outer cap assembly is slidable relative to the inner cap assembly between a first filling position, where the interior of the syringe is in fluid communication with the fluid inlet path, and a second delivery position, where the interior of the syringe is in fluid communication with the fluid outlet path. Syringes including the cap are also described.
A61D 7/00 - Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe
A61J 7/00 - Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/14 - Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
B65B 3/28 - Methods or devices for controlling the quantity of the material fed or filled by weighing
B65B 3/30 - Methods or devices for controlling the quantity of the material fed or filled by volumetric measurement
B65B 7/28 - Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
B65B 57/02 - Automatic control, checking, warning or safety devices responsive to absence, presence, abnormal feed, or misplacement of binding or wrapping material, containers, or packages
69.
METHODS OF INACTIVATION OF VIRUSES USING N-METHYLGLUCAMIDE AND ITS DERIVATIVES
This disclosure relates to methods for use in inactivating viruses. The methods of inactivating viruses with N-methylglucamides is applicable to the purification process of biologically-active drugs such as protein subunits, proteins (enzymes, factors, etc.), recombinant proteins, antibodies, vaccine or gene therapeutic products. The detergents used in this method are based on multiple N-methylglucamide homologs, consisting of a hydrophilic glucose moiety and hydrophobic fatty acid tail, linked by an amide bond. Additionally, these sugar-based detergents are nonionic by nature, which do not disrupt the drug protein, plasma biologies, non-enveloped viral vaccine or adeno associated viral particles. A method of purifying a biological product solution of interest having an unidentified enveloped virus contaminant, including incubating a biological product solution of interest with a standard solution, inactivating any potential enveloped virus contaminant present in the biological product solution of step (a), measuring the inactivated virus present in the final solution of step (b), incubating a separate biological product solution of interest with a N-methylglucamide solution, measuring the inactivated virus present in the final solution of step (d), and comparing the results of the final solutions of step (c) and step (e).
A system and method for correcting a volume of fluid delivered by a fluid injector during an injection procedure is described. The method included determining and compensating for a volume factor associated with compliance of the fluid injector system and correcting for the volume by one of over-driving the distance that the drive member travels in a fluid reservoir, under-driving the distance that the drive member travels in the fluid reservoir, or lengthening or shortening a fluid delivery time.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
A method of delivering a multi-phase fluid injection to a patient via a fluid injector comprising two or more syringes includes injecting a first fluid of the fluid injection from at least a first syringe at a first predetermined flow rate, wherein the first fluid has a first viscosity; injecting an initial portion of a second fluid from at least a second syringe at an intermediate flow rate different than a second predetermined flow rate for a specified time, the second fluid having a second viscosity different from the first viscosity; and injecting a remaining portion of the second fluid of the fluid injection at a flow rate at the second predetermined flow rate. A fluid injector system configured for delivering a multi-phase fluid injection is disclosed.
A method for dynamic pressure control during a multiphase injection is described wherein the pressures of fluids in the various reservoirs of a fluid delivery system are controlled to provide desired fluid delivery parameters. The methods include advancing the first drive member to expel the first fluid from the first reservoir into a conduit, wherein the fluid is pressurized to a first fluid pressure; measuring the first fluid pressure to provide a target value; while the second reservoir is in fluid isolation from the conduit, advancing or retracting the second drive member to increase or decrease the fluid pressure of the second fluid in the second reservoir to the target value; placing the second reservoir in fluid communication with the conduit; and advancing the second drive member to expel the second fluid from the second reservoir into the conduit.
A fluid injector system for delivering a multi-phase fluid injection to a patient and methods of fluid delivery is disclosed. Methods of creating and using a multi-aspect fluid path impedance model of the injector system are used. Modeling and adjustment of factors that affect impedance and prevent or reduce backflow, reduce the likelihood of fluid flow rate spikes and provide more accurate flow rates and mixing ratios of fluids may be repeated or happen essentially continuously during an injection. The adjustments may be determined before the injection or determined and/or adjusted during the injection. The determination may include sensor feedback commonly used in injectors such as pressure and position feedback as well as other sensors. In all cases, the user can be notified of adjustments through on-screen notices and/or through the recordation of the injection data by a control device of the injector at the conclusion of the injection.
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A calibration system for calibrating a pressure output of a fluid injector having a housing configured for connecting to the fluid injector; a drive member engagement portion configured for contacting a drive member of the fluid injector; a compressible member, which may have a known modulus of compression, connected at its proximal end to the drive member engagement portion, wherein the compressible member is compressed with movement of the drive member of the fluid injector between a first, uncompressed position and a second, at least partially compressed position of the fluid injector in a distal direction; and a sensor connected to the compressible member is described. The sensor is configured for measuring at least one of a force imparted by the drive member and a displacement of the drive member when the compressible member is in the second, at least partially compressed position. The system may generate a calibration curve for the drive member of the fluid injector and allow the generation of a fault condition. Methods for calibrating a fluid injector are also described.
The present disclosure provides improved methods for calibrating the zero position of at least one drive member of an injector system is disclosed. Automated methods of position calibration of the drive member of a fluid injector are disclosed. These methods address sources of error in positional accuracy and fluid delivery inaccuracies, such as disposable syringe tolerance and injector wear over time. According to other embodiments of the present disclosure, methods and fluid injector systems for determining and correcting for the amount of slack in a fluid injection apparatus are described. An understanding of the calibration and the amount of slack in a fluid injection system allows a processor to correct for the slack, thereby ensuring more accurate fluid delivery to the patient and more accurate imaging processes.
A method, system, and computer program product for predictive maintenance. A method may include receiving operation data associated with one or more injection systems, wherein the operation data includes one or more operation parameters associated with one or more operations of the one or more injection systems; determining one or more prediction scores for the one or more injection systems based on the operation data, wherein the one or more prediction scores include one or more predictions of one or more operation failures or misuses for the one or more injection systems; and providing maintenance data associated with the one or more operation failures or misuses, wherein the maintenance data is based on the one or more prediction scores.
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
77.
SYSTEMS AND METHODS FOR SPLIT BOLUS PROTOCOL GENERATION
Described is an injector system for implementing a split bolus injection procedure. The injector system includes a processor and a non-transitory storage medium having programming instructions stored therein that, when executed by the processor, enable the injector system to operate as a parameter generation system for use in determining parameters associated with a split bolus injection protocol via which injection of the contrast agent by the injector system is controlled. The split bolus injection protocol includes at least a loading injection and a diagnostic injection, wherein the loading injection is performed before the diagnostic injection, and wherein a pause separates the loading injection from the diagnostic injection. Also described is a method for patient imaging using a split bolus injection technique and a system having an imaging device and the injector system described above.
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
78.
COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER
The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
A child-resistant dispenser includes a housing (110); and a slider (150) disposed on the housing and configured to slide from a closed position to a dispensing position, the slider comprising a movable engagement portion (148) that engages a stop (122) on the housing, wherein the engagement between the movable engagement portion and the stop restricts movement of the slider to the dispensing position and the movable engagement portion is configured to disengage from the stop in response to a release force applied to the slider.
B65D 83/04 - Containers or packages with special means for dispensing contents for dispensing annular, disc-shaped, or spherical or like small articles, e.g. tablets or pills
B65D 43/20 - Non-removable lids or covers linearly slidable
80.
CHILD-RESISTANT DISPENSER, METHOD OF DISPENSING A UNIT OF PRODUCT FROM A DISPENSER
A child-resistant dispenser includes a housing having a first moveable member disposed on a first side of the housing; and a slider disposed in the housing and configured to slide from a closed position to a dispensing position, the slider comprising a first engagement portion that engages a first stop on the housing, wherein the engagement between the first engagement portion and the first stop restricts movement of the slider to the dispensing position and the first moveable member is configured to disengage the first engagement portion from the first stop in response to a first release force applied to the first moveable member.
B65D 83/04 - Containers or packages with special means for dispensing contents for dispensing annular, disc-shaped, or spherical or like small articles, e.g. tablets or pills
81.
CHEWABLE GEL PRODUCTS FOR ACTIVE PHARMACEUTICAL INGREDIENTS
The present disclosure relates to chewable gel products containing a gel carrier and an active pharmaceutical ingredient (API), where the chewable gel product has an acceptable taste.
A61K 9/00 - Medicinal preparations characterised by special physical form
A23L 29/20 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
A23L 29/256 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
A23G 3/36 - Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Described is a system for generating simulated CT images. The system can include a CT imaging simulator, a phantom database, and a scanner database. The phantom database can include one or more virtual phantoms while the scanner database can include information about one or more CT scanners, including a subject CT scanner. The CT imaging simulator can use information about a subject patient, a virtual phantom, and scanner information about the subject CT scanner to generate a simulated CT image that closely simulates what an actual CT image would look like if performed on the subject patient using the subject CT scanner. The simulated CT image can be displayed on a display screen. Also described is a method of generating a simulated CT image and CT image simulator software that can be used to generate a simulated CT image.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A plunger, a syringe, and a method of making a plunger and a syringe are disclosed. The plunger includes a support ring and a cover disposed over and coupled to the support ring. A cavity defining a predetermined volume is defined between the support ring and the cover. The syringe includes a barrel defining an inner wall and the plunger inserted therein.
An engagement mechanism associated with a reciprocally movable piston of a fluid injector is configured for releasably engaging an engagement portion at a proximal end of a rolling diaphragm syringe having a flexible sidewall configured for rolling upon itself when acted upon by the piston. The engagement mechanism has a plurality of engagement elements reversibly and pivotally movable about a pivot pin relative to the engagement portion of the syringe between a first position, where the plurality of engagement elements are disengaged from the engagement portion of the syringe, and a second position, where the plurality of engagement elements are pivotally movable about the pivot pin in a radially inward direction to engage with the engagement portion of the syringe. The engagement mechanism further has a drive mechanism for moving the plurality of engagement elements between the first position and the second position.
An engagement mechanism associated with a reciprocally movable piston of a fluid injector is configured for releasably engaging an engagement portion at a proximal end of a rolling diaphragm syringe having a flexible sidewall configured for rolling upon itself when acted upon by the piston. The engagement mechanism has a plurality of engagement elements reversibly and radially movable relative to the engagement portion of the syringe between a first position, where the plurality of engagement elements are disengaged from the engagement portion of the syringe, and a second position, where the plurality of engagement elements are engaged with the engagement portion of the syringe. The engagement mechanism further has a drive mechanism for moving the plurality of engagement elements between the first position and the second position.
A fluid control valve for use in a fluid delivery system for delivering fluid to a patient includes a valve body defining an internal chamber, a first inlet port for receiving a first inlet tube, a second inlet port for receiving a second inlet tube, an outlet port, and a sliding valve member slidably disposed in the internal chamber. The first inlet tube defines a first inlet lumen axially aligned with the internal chamber. The second inlet tube defines a second inlet lumen axially aligned with the internal chamber. The sliding valve member includes a first sealing end and second sealing end. The sliding valve member is positionable in a first operating state, a second operating state, and a third operating state based on a flow differential between the first inlet lumen and the second inlet lumen.
A pressure jacket configured for connecting to an injector head of a fluid injector has an open distal end, an open proximal end, and a sidewall defining a throughbore extending between the distal end and the proximal end along a longitudinal axis. The throughbore is configured for receiving at least a portion of a syringe. The pressure jacket has at least one syringe retaining element positioned at least partially within the throughbore. The at least one syringe retaining element is configured for engaging at least a portion of the syringe during pressurized delivery of fluid from the syringe to prevent or limit a distal movement of the syringe relative to the pressure jacket.
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A syringe including a syringe body extending from a proximal end to a distal end, and a stabilizing element provided on the distal end of the syringe body, a portion of the stabilizing element extending substantially perpendicular to a longitudinal axis of the syringe body. A multi-use disposable set (MUDS) includes a plurality of syringes, each syringe having a syringe body, a proximal end, a distal end spaced apart from the proximal end along a longitudinal axis of the syringe body, a stabilizing element provided on the distal end, a portion of the stabilizing element extending substantially perpendicular to the longitudinal axis of the syringe body, and a manifold in fluid communication with the distal end of each of the plurality of syringes.
In one aspect of the subject invention, a personal care product is provided herein including an applicator having a body, with a dispensing opening, and a support surface, within the body, which is advanceable towards the dispensing opening. A layer of solid personal care is disposed on the support surface which defines an exposed face bounded by spaced-apart first and second edges extending between first and second ends. The exposed face also defines a first inclined face extending from the first end to a first location between the first and second ends, and a second inclined surface, extending from the second end to a second location between the first and second ends. The first and second inclined faces define an included angle which is less than 180 degrees. Advantageously, with the subject invention, differently dimensioned and angularly disposed surfaces may be defined suitable for applying the personal care to different portions of the body.
A connector assembly may include a body and a fluid fitting, the fluid fitting configured for releasably engaging a syringe nozzle, at least one deflectable locking arm connected to the body and radially deflectable relative to the distal end, the proximal end of the at least one deflectable locking arm configured for deflecting in a radial direction relative to the distal end to releasably engage the syringe nozzle, and at least one locking element disposed on the at least one deflectable locking arm, the at least one locking element movable with movement of the at least one deflectable locking arm between a first position where the at least one locking element is released from an engagement portion of the syringe nozzle and a second position where the at least one locking element is engaged with the engagement portion of the syringe nozzle.
It may be desirable to inject a medical liquid into a patient. In some embodiments there is provided a fill adapter for delivery of a medical liquid to a syringe. The fill adapter includes a body having a distal end, proximal end, and central bore extending between the distal end and proximal end. The central bore has an angled portion at the proximal end. The fill adapter includes a flow controller disposed within the central bore and having a convex curved distal surface. The flow controller defines a gap formed between an outer surface of the convex curved distal surface and an inner surface of the central bore. The convex curved distal surface is shaped to direct liquid flowing through the central bore to flow through the gap, along the angled portion, and along an interior surface of a sidewall of the syringe under a Coanda effect.
A pressure jacket for use with a fluid injector may have a pressure jacket body having a proximal end, a distal end, and a circumferential sidewall extending between the proximal end and the distal end along a pressure jacket longitudinal axis. The pressure jacket may further have at least one resiliently deflectable retaining member having a first segment attached to the pressure jacket body and a second segment protruding from the first segment toward the distal end of the pressure jacket body and deflectable relative to the first segment. The pressure jacket may further have at least one actuation member associated with the at least one resiliently deflectable retaining member. The at least one actuation member may interact with a housing of the fluid injector when the pressure jacket is connected to the housing to deflect the at least one resiliently deflectable retaining member upon rotation of the pressure jacket.
A plunger for use with a syringe has a plunger body with a proximal end, a distal end, and a circumferential sidewall extending between the proximal end and the distal end along a plunger longitudinal axis. The plunger further has at least one resiliently deflectable retaining member having a first segment attached to the plunger body and a second segment protruding toward the distal end of the plunger body and deflectable relative to the first segment. The plunger further has at least one actuation member associated with the at least one resiliently deflectable retaining member. The at least one actuation member interacts with a piston to deflect the at least one resiliently deflectable retaining member upon rotation of the plunger relative to the piston. The plunger is engagable with the piston regardless of a rotational orientation of the piston relative to the plunger.
The present invention is a formulation of naproxen having a release profile that provides immediate pain relief equivalent to taking 440 mg (or 2 tablets of 220 mg) naproxen sodium and also extended pain relief for 24 hours. In particular, the present invention is a single solid-dose combining a unique ratio of an immediate release naproxen sodium product with an extended release naproxen sodium layer. More particularly, the present invention is a single bilayer tablet that immediately releases 300-320 mg of naproxen sodium and thereafter gradually releases 450-480 mg of naproxen sodium. This product is capable of providing 24 hours of pain relief when administered as a single bilayer tablet. The single bilayer tablet provides immediate release (IR) of naproxen sodium for initial pain relief from one layer followed by continuous release of the remaining naproxen sodium from the other layer to maintain extended pain relief up to 24 hours.
A fluid injection system and a fluid verification system for confirming that a syringe, containing a fluid for injection, is fully filled with fluid and neither has free space (i.e., air) near the distal end thereof when the syringe is provided in an upright position nor contains air bubbles. Imaging processing techniques and systems are also provided to determine various injection parameters and to verify the type and certain properties of fluid that is present within a syringe.
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/315 - Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod; Appliances on the rod for facilitating dosing
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
96.
SYSTEM AND METHOD FOR SYRINGE FLUID FILL VERIFICATION AND IMAGE RECOGNITION OF POWER INJECTOR SYSTEM FEATURES
A fluid injection system and a fluid verification system for confiming that a syringe, containing a fluid for injection, is fully filled with fluid and neither has free space (i.e., air) near the distal end thereof when the syringe is provided in an upright position nor contains air bubbles. Imaging processing techniques and systems are also provided to determine various injection parameters and to verify the type and certain properties of fluid that is present within a syringe.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
97.
SYSTEM AND METHOD FOR SYRINGE FLUID FILL VERIFICATION AND IMAGE RECOGNITION OF POWER INJECTOR SYSTEM FEATURES
A fluid injection system comprises a fluid injector; at least one syringe operatively engaged with the injector and configured to be illuminated with an electromagnetic radiation source to illuminate fluid contained therein; a sensor positioned to capture an image of the illuminated fluid; and a computing device in communication with the injector and the sensor. The computing device includes a processor configured to: obtain from the sensor the image of the illuminated fluid; determine, based on the i mage, a type of the fluid contained within the syringe(s); and automatically display on a display device in communication with the processor an indication of the type of the fluid contained within the syringe(s). Measurements performed in a region of interest in the image of the illuminated fluid by determining an average brightness value of pixels in the region of interest are utilized to determine the type of fluid contained within the syringe(s).
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
98.
SYSTEM AND METHOD FOR SYRINGE FLUID FILL VERIFICATION AND IMAGE RECOGNITION OF POWER INJECTOR SYSTEM FEATURES
A fluid injection system and a fluid verification system for confirming that a syringe, containing a fluid for injection, is fully filled with fluid and neither has free space (i.e., air) near the distal end thereof when the syringe is provided in an upright position nor contains air bubbles. Imaging processing techniques and systems are also provided to determine various injection parameters and to verify the type and certain properties of fluid that is present within a syringe.
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
G06T 7/90 - Determination of colour characteristics
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
G06V 10/40 - Extraction of image or video features
G06V 10/56 - Extraction of image or video features relating to colour
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
G06K 7/10 - Methods or arrangements for sensing record carriers by corpuscular radiation
99.
SYSTEM AND METHOD FOR SYRINGE FLUID FILL VERIFICATION AND IMAGE RECOGNITION OF POWER INJECTOR SYSTEM FEATURES
A fluid injection system and a fluid verification system for confirming that a syringe, containing a fluid for injection, is fully filled with fluid and neither has free space (i.e., air) near the distal end thereof when the syringe is provided in an upright position nor contains air bubbles. Imaging processing techniques and systems are also provided to determine various injection parameters and to verify the type and certain properties of fluid that is present within a syringe.
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A fluid injection system includes an injector, afluid path set, a purge container having a feature provided on the container body, an image capture device, and a computing device. The image capture device is positioned to capture an image of the feature through a content of the body. The computing device includes a processor configured to: obtain the image of the feature through the fluid within the body; determine, based on the image, an appearance of the feature; compare the determined appearance with a template of an appearance of the feature when viewed through a fluid provided for an injection; determine that the fluid path set has been purged and primed if the determined appearance matches the template; and automatically display on a display device an indication that the fluid path set has been purged and primed and the injector is ready for the injection based on the determination.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
patents
